Evidence map›Paper›PMID 34354918›Full record

ArticleRespiratory medicine case reports2021

A case of hemothorax secondary to intrapleural fibrinolytic therapy: Considerations for use of fibrinolytics in high-risk patients.

Naureen Narula, Nakul Katyal, Mohammed Salem, Akshay Avula, Abdulhassan Siddiqui, Rabih Maroun, Michel Chalhoub

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Respiratory medicine case reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 92% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Naureen NarulaDepartment of Pulmonary and Critical Care, Staten Island University Hospital, Staten Island, NY, USA.
Nakul KatyalDepartment of Neurology, University of Missouri, Columbia, MO, USA.
Mohammed SalemDepartment of Internal Medicine, Staten Island University Hospital, Staten Island, NY, USA.
Akshay AvulaDepartment of Pulmonary and Critical Care, Staten Island University Hospital, Staten Island, NY, USA.
Abdulhassan SiddiquiDepartment of Pulmonary and Critical Care, Christie Clinic, Champagne, Illinois, USA.
Rabih MarounDepartment of Pulmonary and Critical Care, Staten Island University Hospital, Staten Island, NY, USA.
Michel ChalhoubDepartment of Pulmonary and Critical Care, Staten Island University Hospital, Staten Island, NY, USA.
Staten Island University Hospital · USUniversity of Missouri · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Indwelling Pleural Catheters (IPC) are increasingly being used for management of recurrent pleural effusions (RPEs). Use of IPC for management of both malignant and non-malignant recurrent pleural effusions has been associated with complications such as dysfunctional or nonfunctioning IPCs. Alteplase, a tissue plasminogen activator (tPA) is often used to restore flow of non-draining IPC in symptomatic patients. We present a case of a sixty-eight-year old patient with life-threatening pleural hemorrhage following intrapleural catheter instillation of tPA that was managed successfully by thoracotomy. Our case describe the importance of individualizing the fibrinolytic dose, frequency and the indwelling time in high risk patients. We have reviewed the current literature and recommendations for use of fibrinolytic therapy for IPC in high risk patients on anticoagulation.

Indexed as

ComplicationsHemothoraxIndwelling pleural catheters (IPCs)Malignant pleural effusionsRecurrent pleural effusions (RPEs)

Identifiers

PMID34354918
PMCPMC8322142
OpenAlexW3160107989

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.